Newer antifungal therapy for emerging fungal pathogens.
As the number of immunocompromised patients increases, there is a concomitant increase in the number and diversity of fungal infections. Fungi that were once considered harmless or contaminants are now pathogenic in the immunocompromised host. Often these emerging pathogens are indistinguishable from the more familiar fungal infections; however, they are generally more recalcitrant to conventional antifungal therapies. With the antifungal armamentarium now expanding, the clinician now has many more options for these difficult-to-treat mycoses. We review many of the newer antifungal agents (second-generation triazoles, echinocandins, etc.) as therapeutic options for the recently emerging fungal pathogens.
Steinbach
William J
WJ
Division of Pediatric Infectious Diseases, Duke University Medical Center, Box 3499, Durham, NC 27710, USA. bill.steinbach@duke.edu
Perfect
John R
JR
D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D021821:Communicable Diseases, Emerging / Q000188:drug therapy* / Q000382:microbiology*; D005658:Fungi / Q000145:classification / Q000187:drug effects / Q000302:isolation & purification / Q000502:physiology; D006801:Humans; D009181:Mycoses / Q000188:drug therapy* / Q000382:microbiology
D000935:Antifungal Agents